Medpace's Three Book-To-Bill Shareholder Suits Are Dropped, Then A $1 Billion Buyback Is Approved

Plaintiffs withdrew all three suits without prejudice as the board replaced its repurchase authorization, Medpace's 10-Q shows.

Share
Medpace's Three Book-To-Bill Shareholder Suits Are Dropped, Then A $1 Billion Buyback Is Approved

Plaintiffs voluntarily dropped all three shareholder suits over Medpace's book-to-bill ratio within eight days, according to the company's 10-Q. Medpace, a clinical contract research organization that runs drug and device trials for others, also replaced its stock repurchase authorization with a new one of up to $1.0 billion.

Three suits, three dismissals

The class action, which alleged Medpace misled the market about its book-to-bill ratio (new orders relative to revenue), was dismissed by the plaintiff on October 12. Two derivative suits, which named the CEO and directors over the same statements, were dismissed on October 20. All three notices were without prejudice, so the claims could be refiled.

Medpace's prior quarterly filing explained that it booked no liability for the matter, since a loss was neither probable nor reasonably estimable. The new filing no longer contains that sentence.

A bigger buyback, after a quiet quarter

Medpace bought no shares in the third quarter. In the nine months through September 30 it repurchased 705,616 shares for $294.7 million, and it had $527.0 million left on the old program.

On October 20 the board ended that authorization, which was set to expire December 31, 2026, and approved up to $1.0 billion of repurchases through December 31, 2028, funded from cash on hand, according to an 8-K. The company has no obligation to buy any minimum amount.

Medpace held $705.3 million in cash and had no debt at September 30. The stock closed at $653.96 on Thursday, down 1.29%.

Third-quarter results

Revenue rose 8.5% to $716.0 million, and net income reached $137.5 million, or $4.84 per diluted share, from $111.1 million, or $3.86, a year earlier. Net new business awards were $873.4 million, and backlog stood at $3,167.2 million, up 5.6% from a year earlier.

Related-party revenue fell to $3.8 million from $12.2 million, with CinRx alone dropping to $2.3 million from $10.4 million.

The next test is the fourth quarter, when the first purchases under the new $1.0 billion authorization could show up in the company's share count.

Sources

More on Medpace Holdings

All Medpace Holdings (MEDP) coverage →